TG Therapeutics, Inc (NASDAQ:TGTX) shares rose 5.3% during trading on Monday . The stock traded as high as $14.10 and last traded at $13.80. Approximately 1,034,289 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 1,410,404 shares. The stock had previously closed at $13.10.
Several research analysts have recently issued reports on TGTX shares. BidaskClub upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 16th. B. Riley reiterated a “buy” rating and issued a $27.00 price objective (up from $21.50) on shares of TG Therapeutics in a report on Friday, March 9th. Finally, Raymond James reiterated a “buy” rating on shares of TG Therapeutics in a report on Thursday, April 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $24.60.
The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -7.20 and a beta of 1.21.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.15). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 170.83% and a negative net margin of 87,025.00%. analysts predict that TG Therapeutics, Inc will post -1.99 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of TGTX. Senzar Asset Management LLC lifted its position in shares of TG Therapeutics by 56.9% in the 4th quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock valued at $11,112,000 after acquiring an additional 491,678 shares in the last quarter. CIBC World Markets Inc. purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $250,000. University of Notre Dame DU Lac purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at approximately $2,483,000. Allianz Asset Management GmbH lifted its position in shares of TG Therapeutics by 6.6% in the 4th quarter. Allianz Asset Management GmbH now owns 137,980 shares of the biopharmaceutical company’s stock valued at $1,131,000 after acquiring an additional 8,602 shares in the last quarter. Finally, Dupont Capital Management Corp lifted its position in shares of TG Therapeutics by 153.1% in the 4th quarter. Dupont Capital Management Corp now owns 64,957 shares of the biopharmaceutical company’s stock valued at $533,000 after acquiring an additional 39,295 shares in the last quarter. Hedge funds and other institutional investors own 47.35% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.